Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)242.09
  • Today's Change8.59 / 3.68%
  • Shares traded249.00
  • 1 Year change+54.61%
  • Beta0.4794
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

  • Revenue in USD (TTM)841.62m
  • Net income in USD-266.50m
  • Incorporated2006
  • Employees1.19k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arrowhead Pharmaceuticals Inc1.09bn202.27m9.01bn711.0041.7515.5534.828.261.541.547.904.140.8335--9.861,534,432.0017.84-25.9621.44-30.82----21.41-76.01--5.910.5068--23,258.1556.6399.73--13.66--
BIO-TECHNE Corp1.22bn79.96m9.05bn3.10k113.924.4849.247.440.50760.50767.7412.900.46822.066.04392,121.603.087.623.278.1366.6067.496.5816.743.0856.920.114526.725.2310.55-56.35-20.37-9.74-4.36
Praxis Precision Medicines Inc0.00-303.27m9.21bn168.00--9.49-----13.45-13.450.0034.850.00----0.00-42.68-61.92-45.82-68.99-------9,004.13----0.00---100.00---65.88------
Tempus AI Inc1.27bn-245.03m9.53bn3.80k--19.34--7.49-1.41-1.417.302.760.794610.525.46334,681.30-15.31-41.14-19.31-55.0662.7454.59-19.27-55.733.00-3.900.7161--83.4146.5767.17--15.24--
Madrigal Pharmaceuticals Inc958.40m-288.28m9.99bn915.00--16.51--10.43-12.85-12.8542.7226.390.83271.0310.181,047,435.00-25.05-53.85-31.64-68.4394.14---30.08-146.243.77--0.3606--432.05--38.12--59.68--
Exelixis Inc2.32bn782.57m10.66bn1.08k14.744.9813.134.592.782.788.238.230.80113.808.402,154,249.0027.0213.6831.4115.6596.3996.3333.7320.553.50--0.000.006.9818.6350.1347.58-22.60--
Immunitybio Inc113.29m-351.40m10.73bn691.00------94.75-0.3898-0.38980.1232-0.49460.25610.1645.04163,947.90-79.44-101.72-91.74-204.7899.34---310.25-1,629.945.08-1.752.64--668.31184.7615.03--20.57--
Summit Therapeutics Inc0.00-1.08bn12.55bn265.00--19.05-----1.44-1.440.000.84970.00----0.00-181.94-113.04-201.41-124.75-------82,864.48----0.00-------387.81--9.31--
Regencell Bioscience Holdings Ltd0.00-3.58m12.91bn12.00--2,655.44-----0.0073-0.00730.000.00980.00----0.00-50.50-53.93-53.75-65.67------------0.00------16.68--5.32--
Medpace Holdings Inc2.53bn451.12m12.98bn5.90k29.9228.2027.095.1315.2915.2985.6716.221.24--7.24428,853.2022.1318.5255.4237.5330.0629.6017.8317.15----0.000.0019.9722.2711.5725.500.0102--
Ionis Pharmaceuticals Inc943.71m-381.39m13.54bn1.40k--27.37--14.35-2.47-2.475.692.990.28921.4111.93673,117.00-11.69-10.64-14.03-12.4098.3198.40-40.41-39.123.81--0.8266--33.835.2915.97--7.93--
Ascendis Pharma A/S (ADR)841.62m-266.50m15.00bn1.19k------17.83-4.37-4.3713.69-3.070.58030.31794.68707,839.40-18.37-38.61-90.34-89.3886.8285.86-31.67-145.760.7551-1.691.23--98.03152.9639.69---17.01--
Exact Sciences Corp3.25bn-207.95m19.73bn7.10k--8.211,439.506.08-1.10-1.1017.2112.580.55095.9911.86457,322.50-3.53-8.66-3.99-9.5469.6970.20-6.40-21.532.17--0.4935--17.6916.8479.79---15.13--
Revolution Medicines Inc0.00-1.13bn20.14bn883.00--12.27-----5.94-5.940.008.280.00----0.00-46.06-34.12-50.75-37.02-------3,410.03----0.1413-------88.52--40.38--
Data as of Mar 02 2026. Currency figures normalised to Ascendis Pharma A/S's reporting currency: US Dollar USD

Institutional shareholders

64.22%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 31 Dec 202510.28m16.59%
Westfield Capital Management Co. LPas of 31 Dec 20255.19m8.37%
Avoro Capital Advisor LLCas of 31 Dec 20255.11m8.25%
Janus Henderson Investors US LLCas of 31 Dec 20253.92m6.33%
Fidelity Management & Research Co. LLCas of 31 Dec 20253.80m6.13%
Artisan Partners LPas of 31 Dec 20253.23m5.21%
Capital Research & Management Co. (International Investors)as of 31 Dec 20253.06m4.94%
Massachusetts Financial Services Co.as of 31 Dec 20251.83m2.95%
Wellington Management Co. LLPas of 31 Dec 20251.72m2.77%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20251.67m2.69%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.